Is Healthcare Global Enterprises Ltd (HCG) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a average quality company .

Is Healthcare Global Enterprises Ltd (HCG) undervalued or overvalued?

The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Healthcare Global Enterprises Ltd (HCG) share price return in the past 10 years?

Healthcare Global Enterprises Ltd share price has appreciated 11.4% annually (CAGR) over the past ten years.

Is Healthcare Global Enterprises Ltd (HCG) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Healthcare Global Enterprises Ltd (HCG)?

Company share prices are keep on changing according to the market conditions. The current trading price of Healthcare Global Enterprises Ltd (HCG) on 17-Apr-2026 16:59:59 at 16:59 is 566.55.

What is the market cap of Healthcare Global Enterprises Ltd (HCG)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Healthcare Global Enterprises stood at Rs. 8458.72 Cr.

What is the P/E ratio of Healthcare Global Enterprises?

The latest standalone P/E ratio of Healthcare Global Enterprises as of 17-Apr-2026 is 364.60.

What is the P/B ratio of Healthcare Global Enterprises Ltd (HCG)?

The latest standalone P/B ratio of Healthcare Global Enterprises Ltd (HCG) as of 17-Apr-2026 is 5.26.

What is the 52-week high and low of Healthcare Global Enterprises Ltd (HCG)?

The 52-week high of Healthcare Global Enterprises Ltd (HCG) is Rs. 799.36 and the 52-week low is Rs. 511.83.

What is the TTM revenue of Healthcare Global Enterprises Ltd (HCG)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Healthcare Global Enterprises is Rs. 1338.04 (Cr.).

Healthcare Global Enterprises Ltd (HCG) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Healthcare Global Enterprises Ltd (HCG)
Brand: Healthcare Global Enterprises

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	4%	6.1%	7.7%	6.1%	1.6%	-12.6%	10.5%	8%	7.3%	6%	-
Value Creation Index ⓘ	-0.7	-0.6	-0.5	-0.6	-0.9	-1.9	-0.3	-0.4	-0.5	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	471	545	586	641	688	609	850	1,006	1,171	1,277	1,338
Sales YoY Gr.	-	15.7%	7.6%	9.3%	7.5%	-11.6%	39.6%	18.3%	16.4%	9%	-
Adj EPS ⓘ	-0.2	2.2	2	0.8	-6.1	-15.2	0.1	3.1	3.1	2	1.6
YoY Gr.	-	NA	-11.2%	-60.8%	-878.2%	NA	NA	4271.4%	1.3%	-36.1%	-
BVPS (₹) ⓘ	60.6	63.1	69.2	72.3	68.1	69.2	78	81	83.1	83.3	107.7
Adj Net Profit ⓘ	-1.8	19.3	17.4	6.9	-54.2	-192	1	42.8	43.4	27.8	23
Cash Flow from Ops. ⓘ	57.8	53.9	66.4	87	86.3	70.9	124	130	209	146	-
Debt/CF from Ops. ⓘ	3.4	4	4	4.9	5.7	3.4	0.9	0.9	2	4.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.7%	13.2%	14.5%	9%
Adj EPS ⓘ	NA	NA	204.7%	-36.1%
BVPSⓘ	3.6%	4.1%	2.2%	0.3%
Share Price	11.4%	27.8%	29.2%	-4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-0.5	3.6	2.9	1.1	-8.6	-24.9	0.1	3.8	3.7	2.3	1.6
Op. Profit Mgn % ⓘ	13.6	15.2	14	14.7	16.8	12.1	17.3	16.9	17.1	16.6	16.8
Net Profit Mgn % ⓘ	-0.4	3.5	3	1.1	-7.9	-31.5	0.1	4.3	3.7	2.2	1.7
Debt to Equity ⓘ	0.4	0.4	0.4	0.7	0.8	0.3	0.1	0.1	0.4	0.6	-
Working Cap Days ⓘ	128	130	161	211	240	257	150	124	134	153	80
Cash Conv. Cycle ⓘ	-18	-16	-3	10	22	38	26	26	22	21	-0

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 14.52%

Net Profit is growing at healthy rate in last 3 years 204.69%

Return on Equity has declined versus last 3 years average to 1.60%

Sales growth is not so good in last 4 quarters at 6.64%

	Standalone	Consolidated
TTM EPS (₹)	1.6	1.3
TTM Sales (₹ Cr.)	1,338	2,477
BVPS (₹) ⓘ	107.7	89.6
Reserves (₹ Cr.) ⓘ	1,458	1,188
P/BV ⓘ	5.26	6.32
PE ⓘ	364.60	446.37

From the Market
52 Week Low / High (₹)	511.83 / 799.36
All Time Low / High (₹)	62.56 / 799.36
Market Cap (₹ Cr.)	8,459
Equity (₹ Cr.)	149.3
Face Value (₹)	10
Industry PE ⓘ	86.1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	471	545	586	640	688	609	850	1,006	1,171	1,277
Operating Expenses ⓘ +	407	462	504	546	573	535	703	837	970	1,065
Manufacturing Costs	141	158	159	192	215	196	241	273	312	350
Material Costs	134	149	155	153	147	138	210	236	281	318
Employee Cost	85	98	116	130	143	137	157	175	205	221
Other Costs ⓘ	48	57	75	71	69	65	95	153	171	177
Operating Profit ⓘ	64	83	82	94	116	73	147	169	201	211
Operating Profit Margin (%)	13.5%	15.2%	13.9%	14.7%	16.8%	12.1%	17.3%	16.8%	17.1%	16.6%
Other Income ⓘ +	3	7	23	13	12	24	12	22	16	39
Exceptional Items ⓘ	-4	0	3	0	-31	-153	53	-3	-16	-35
Interest ⓘ	34	16	27	48	83	63	43	41	50	84
Depreciation ⓘ	37	44	44	47	79	87	88	89	97	111
Profit Before Tax ⓘ	-9	29	37	13	-65	-205	81	58	54	20
Tax ⓘ	-4	10	12	5	-12	-14	43	17	21	16
Profit After Tax	-5	19	25	7	-53	-192	38	40	33	4
PAT Margin (%)	-1.0%	3.6%	4.3%	1.1%	-7.7%	-31.5%	4.5%	4.0%	2.8%	0.3%
Adjusted EPS (₹)	-0.6	2.3	2.9	0.8	-6.0	-15.2	2.7	2.9	2.3	0.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	519	544	605	639	607	873	1,091	1,133	1,164	1,169
Share Capital ⓘ	85	86	87	88	89	125	139	139	139	139
Reserves ⓘ	434	458	518	551	519	748	952	994	1,025	1,030
Debt +	160	165	219	396	419	214	83	113	375	583
Long Term Debt	123	124	217	346	315	147	82	113	274	304
Short Term Debt	37	41	2	50	104	67	1	0	101	280
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	97	105	114	106	99	81	96	109	148	152
Others Liabilities ⓘ	60	96	165	259	628	379	374	375	552	699
Total Liabilities ⓘ	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,239	2,604
Fixed Assets
Net Fixed Assets ⓘ +	431	442	492	547	914	745	774	788	974	1,038
Gross Block	467	511	591	693	1,141	1,058	1,177	1,275	1,566	1,699
Accumulated Depreciation	36	69	99	146	227	313	403	487	592	661
CWIP ⓘ	29	33	79	104	44	28	5	9	36	23
Investments ⓘ	155	141	219	299	316	366	439	475	506	696
Inventories	11	15	17	16	13	12	17	21	23	20
Trade Receivables	69	101	126	146	152	147	160	212	221	262
Cash Equivalents	50	75	15	9	15	14	120	80	237	264
Others Assets ⓘ	91	103	155	280	300	235	129	144	241	302
Total Assets ⓘ	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,239	2,604

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	58	54	66	87	86	71	124	130	209	146
PBT ⓘ	-9	29	37	13	-65	-205	81	58	54	20
Adjustment ⓘ	74	57	60	91	192	285	79	150	174	227
Changes in Working Capital ⓘ	-0	-25	-32	10	-20	-49	-21	-60	14	-82
Tax Paid ⓘ	-8	-7	1	-26	-20	40	-15	-17	-33	-19
Cash Flow From Investing Activity ⓘ +	-86	-73	-185	-208	-116	-246	49	-138	-254	-347
Capex	-90	-40	-104	-123	-80	-23	-42	-95	-129	-33
Net Investments	-3	2	20	-15	4	-102	189	-10	-47	-112
Others ⓘ	7	-35	-100	-70	-40	-120	-99	-32	-78	-202
Cash Flow From Financing Activity ⓘ +	120	-14	91	66	-3	236	-41	-42	96	-42
Net Proceeds from Shares ⓘ	271	7	35	0	20	453	132	1	2	2
Net Proceeds from Borrowing ⓘ	-110	-9	79	106	36	-219	-67	14	167	57
Interest Paid ⓘ	-33	-12	-23	-40	-66	-59	-43	-36	-48	-90
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-8	0	0	0	7	62	-63	-21	-25	-10
Net Cash Flow ⓘ	92	-33	-27	-55	-32	61	132	-49	51	-243

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-1.2	3.67	4.33	1.16	-8.55	-25.87	3.9	3.61	2.86	0.3
ROCE (%)	3.98	6.12	7.65	6.13	1.62	-12.55	10.46	8.02	7.25	6.03
Asset Turnover Ratio	0.62	0.62	0.58	0.51	0.44	0.37	0.53	0.6	0.59	0.53
PAT to CFO Conversion(x)	N/A	2.84	2.64	12.43	N/A	N/A	3.26	3.25	6.33	36.5
Working Capital Days
Receivable Days	52	57	71	77	79	90	66	68	68	69
Inventory Days	9	9	10	10	8	7	6	7	7	6
Payable Days	235	248	259	263	256	238	154	159	167	172

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.

The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.

The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.

Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.

Business area of the company

The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.

Major events and milestones

2005: Entered into the clinical laboratory business through acquisition of Triesta Sciences Inc. and Triesta Sciences (India) Private Limited.
2006: India Development Fund made its first investment of Rs 500 million in the company,
2006: BMORCL became its subsidiary.
2007: HCG Medi-Surge became its subsidiary.
2007: Evolvence made its first investment of Rs 225 million in the company,
2008: NTICPL made its first investment of Rs 400 million in the company.
2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
2011: Amalgamation of BMORCL with the company.
2011: PIOF became a Shareholder by purchasing shares from NTICPL.
2013: V-Sciences made its first investment of Rs 600 million in the company.
2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
2014: Demerger of multispecialty division from HCG Medi-Surge and vesting of the same with the company.
2015: HCG Regency became its subsidiary.
2015: Amalgamation of HCG Vijay with the company.

Awards and accreditations

2010: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
2011: The company and its Triesta Reference Laboratory received CAP accreditation valid up to August 25, 2015.
2011: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
2012: HCG cancer centre at Bengaluru received NABH accreditation valid up to May 11, 2018.
2013: The company received the ‘Best Place to Work in Indian Healthcare’ award from People Strong and HOSMAC.
2013: HMS, Ahmedabad received NABH accreditation valid up to June 22, 2016.
2013: Triesta Reference Laboratory received accreditation from the National Accreditation Board for Testing and Caliberation Laboratories for its facilities at HCG Tower, Bengaluru in the field of medical testing valid up to October 13, 2015.
2013: The company was designated an ESMO Designated Centre of Integrated Oncology and Palliative Care.
2013: The company received the ‘Most Innovative Single Specialty Healthcare Entity’ award from VC Circle.
2014: The company received the ‘Golden Peacock Award for Innovation in Management’ from the Institute of Directors.
2014: Its pathology laboratory at HMS received ISO 9001 certification valid up to August 30, 2017.
2015: The company received recognition from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India for its in-house research and development wing at HCG Tower, Bengaluru.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Healthcare Global Enterprises Ltd (HCG) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

HealthcareGlobal Share Price